# Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

> **NCT07680439** · PHASE2 · RECRUITING · sponsor: **BrainChild Bio, Inc** · enrollment: 75 (estimated)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- DIPG
- Brain Tumor
- CNS Tumor
- Central Nervous System Tumor
- Pediatric Cancer
- Adult Cancer Patients
- CNS Tumor, Childhood
- CNS Tumor, Adult
- Brainstem Glioma
- Diffuse Midline Glioma
- DMG

## Interventions

- **BIOLOGICAL:** BCB-276

## Key facts

- **NCT ID:** NCT07680439
- **Lead sponsor:** BrainChild Bio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-10
- **Final completion:** 2030-07
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680439, "Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07680439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*